Methods of treating CXCR4-expressing cancers
Some embodiments of this invention include methods for treating disease and methods for administering a compound of Formula (I). In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of Formula (I). Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I).
1. A method for treating a CXCR4 expressing cancer in an animal comprising
administering a composition comprising a compound of Formula (I) to the animal,
wherein the CXCR4 expressing cancer is breast cancer, ovarian cancer, colon cancer, melanoma, squamous cell carcinoma, chronic lymphocytic leukemia, rectal cancer, lung cancer, or prostate cancer, and
the compound of Formula (I) is
2. The method of claim 1 , further comprising identifying an animal with the CXCR4 expressing cancer.
3. The method of claim 1 , wherein the CXCR4 expressing cancer comprises a cancerous tumor.
4. The method of claim 1 , wherein the CXCR4 expressing cancer comprises a cancerous tumor and the treating results in a decrease in the size of the cancerous tumor.
5. The method of claim 1 , wherein the CXCR4 expressing cancer comprises a cancerous tumor and the treating results in a decrease in the number of cancerous tumors.
6. The method of claim 1 , wherein the CXCR4 expressing cancer is metastasized.
7. The method of claim 1 , wherein the CXCR4 expressing cancer is metastasized to the breasts, ovaries, colon, rectum, lungs, or prostate.
8. The method of claim 1 , wherein the CXCR4 expressing cancer is breast cancer or lung cancer.
9. The method of claim 1 , wherein the administering is part of an adjuvant treatment.
10. The method of claim 1 , wherein the compound of Formula (I) inhibits chemotaxis.
11. The method of claim 1 , wherein the compound of Formula (I) inhibits intracellular calcium mobilization.
12. The method of claim 1 , wherein the treating results in at least one of modulation of tumor cell migration or modulation of homing of the neoplastic cells.
13. The method of claim 1 , wherein the compound of Formula (I) modulates activity of CXCR4.
14. The method of claim 1 , wherein the animal is a mammal.
15. The method of claim 1 , wherein the animal is a human.
16. The method of claim 1 , wherein the administering is by an oral route or by a parenteral route.
17. The method of claim 1 , wherein the treating comprises treating metastasis of breast cancer, ovarian cancer, colon cancer, melanoma, chronic lymphocytic leukemia, rectal cancer, lung cancer, or prostate cancer.
18. A method for treating a CXCR4 expressing cancer in an animal comprising
administering a composition comprising a compound of Formula (I) to the animal,
wherein the CXCR4 expressing cancer is breast cancer, ovarian cancer, colon cancer, melanoma, squamous cell carcinoma, chronic lymphocytic leukemia, rectal cancer, lung cancer, or prostate cancer, and
the compound of Formula (I) is
19. The method of claim 18 , further comprising identifying an animal with the CXCR4 expressing cancer.
20. The method of claim 18 , wherein the CXCR4 expressing cancer comprises a cancerous tumor.
21. The method of claim 18 , wherein the CXCR4 expressing cancer comprises a cancerous tumor and the treating results in a decrease in the size of the cancerous tumor.
22. The method of claim 18 , wherein the CXCR4 expressing cancer comprises a cancerous tumor and the treating results in a decrease in the number of cancerous tumors.
23. The method of claim 18 , wherein the CXCR4 expressing cancer is metastasized.
24. The method of claim 18 , wherein the CXCR4 expressing cancer is metastasized to the breasts, ovaries, colon, rectum, lungs, or prostate.
25. The method of claim 18 , wherein the CXCR4 expressing cancer is breast cancer or lung cancer.
26. The method of claim 18 , wherein the administering is part of an adjuvant treatment.
27. The method of claim 18 , wherein the compound of Formula (I) inhibits chemotaxis.
28. The method of claim 18 , wherein the compound of Formula (I) inhibits intracellular calcium mobilization.
29. The method of claim 18 , wherein the treating results in at least one of modulation of tumor cell migration or modulation of homing of the neoplastic cells.
30. The method of claim 18 , wherein the compound of Formula (I) modulates activity of CXCR4.
31. The method of claim 18 , wherein the animal is a mammal.
32. The method of claim 18 , wherein the animal is a human.
33. The method of claim 18 , wherein the administering is by an oral route or by a parenteral route.
34. The method of claim 18 , wherein the treating comprises treating metastasis of breast cancer, ovarian cancer, colon cancer, melanoma, chronic lymphocytic leukemia, rectal cancer, lung cancer, or prostate cancer.